Baby KJ's Gene Therapy Success: A Milestone in Treating Rare Disorders
Baby KJ, born with a rare and life-threatening urea cycle disorder, has made remarkable progress after receiving a groundbreaking gene therapy. The infant, diagnosed with CPS1 deficiency, was discharged from the hospital and has since appeared on national TV, thanks to a successful treatment developed by Dr. Kiran Musunuru and his team.
The journey began when Musunuru and Dr. Rebecca Ahrens-Niklas identified the specific CPS1 mutations in Baby KJ. They designed a bespoke base editing treatment, which was approved by the FDA as a single-patient IND in just seven days. Baby KJ received three doses of the lipid nanoparticle/custom base editor with no severe side effects. The treatment has partially restored Baby KJ's urea cycle function, significantly improving his health.
The rapid progress was made possible by a public-private partnership involving Aldevron, IDT, Acuitas Therapeutics, and The Jackson Laboratory. Musunuru's team is now working on advancing gene-editing therapies to treat sickle cell disease, the genetic disorder also diagnosed in Baby KJ. Preclinical studies and early-stage clinical trials are underway to correct the mutation in patients' hematopoietic stem cells.
Baby KJ's successful gene therapy treatment has opened doors for further advancements in treating rare genetic disorders. Musunuru's team continues to push the boundaries of gene editing, with ongoing research focused on improving the lives of those affected by these conditions.
Read also:
- Medical professional advocates for increased action to address deficiency of primary care physicians
- Treating hypertension can potentially add a decade to a person's life span.
- Unveiled Accounts of Female Scientists Whose Genius Remained Unnoticed
- Yucatan Health Official Accused of Extortion, Business Groups Demand Justice
